Mary Crowley Cancer Research Centers Medical City

Dallas, Texas 75231

0 studies enrolling now · 8 studies all time

What they study most

Advanced Non-Central Nervous System (CNS) Malignancies, Advanced Solid Tumors, Any T-cell Malignancy, Bile Duct Cancer, Bladder Cancer, Breast Neoplasm Malignant Primary, Burkett's Lymphoma, CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Cancer, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Cholangiocarcinoma

Studies at this site

• Study of ORIC-101 in Combination With Anticancer Therapy — Stopped early
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene — Completed
• A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies — Stopped early
• Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer — Stopped early
• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer — Completed
• Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment — Completed
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers — Completed
• Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) — Completed